- AU$55.38bn
- AU$72.46bn
- $15.56bn
Australia's CSL tumbles to near 8-year low after CEO retires, HY profit slips
Australian biotech firm CSL tanks 17% after CEO departure, weak first-half earnings
Australia's CSL profit falls 7% on weaker plasma sales, lifts buyback to $750 million (updated)
Australia's CSL posts a 7% drop in first-half profit
Brief: CSL Declares Interim Dividend Of $1.30 Per Share
Australian biotech firm CSL CEO Paul McKenzie to retire (updated)
Australian biotech firm CSL says CEO Paul McKenzie to retire
Brief: CSL Says Paul Mckenzie Retires As CEO, Gordon Naylor Appointed Interim CEO
CSL's Memo deal signals new R&D philosophy, Jefferies says
Brief: Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Jefferies sees low risk of earnings impact for CSL from potential US regulatory review
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Australia's CSL falls; Macquarie cuts PT, lowers rating on weaker outlook
Macquarie cuts PT, downgrades rating for Australia's CSL on weaker outlook
Jefferies sees CSL's China albumin hit as short-term; keeps PT unchanged
Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound